KEGG   DRUG: Calaspargase pegol
Entry
D10096                      Drug                                   
Name
Calaspargase pegol (USAN);
Calaspargase pegol-mknl;
Asparlas (TN)
Product
ASPARLAS (Servier Pharmaceuticals LLC)
Sequence
LPNITILATG GTIAGGGDSA TKSNYTAGKV GVENLVNAVP QLKDIANVKG EQVVNIGSQD
MNDDVWLTLA KKINTDCDKT DGFVITHGTD TMEETAYFLD LTVKCDKPVV MVGAMRPSTS
MSADGPFNLY NAVVTAADKA SANRGVLVVM NDTVLDGRDV TKTNTTDVAT FKSVNYGPLG
YIHNGKIDYQ RTPARKHTSD TPFDVSKLNE LPKVGIVYNY ANASDLPAKA LVDAGYDGIV
SAGVGNGNLY KTVFDTLATA AKNGTAVVRS SRVPTGATTQ DAEVDDAKYG FVASGTLNPQ
KARVLLQLAL TQTKDPQQIQ QIFNQY
(Disulfide bridge: 77-105, 77'-105', 77''-105'', 77'''-105''')
  Type
Peptide
Source
Escherichia coli [TAX:562]
Remark
Product: D10096<US>
Efficacy
Antineoplastic, Enzyme (L-asparaginase)
  Disease
Acute lymphoblastic leukemia [DS:H00001 H00002]
Comment
SC-PEG Asparaginase
Brite
USP drug classification [BR:br08302]
 Antineoplastics
  Antineoplastics, Other
   Calaspargase pegol
    D10096  Calaspargase pegol (USAN)
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D10096
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D10096
Other DBs
PubChem: 135626814
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system